6533b838fe1ef96bd12a3c3c
RESEARCH PRODUCT
Glutathione Peroxidase-1 and Homocysteine for Cardiovascular Risk Prediction
Christoph BickelRenate B. SchnabelThomas MünzelChristine Espinola-kleinBlankenberg StefanHans J. RupprechtEdith LubosMichael TorzewskiKarl J. LacknerFrançois CambienLaurence Tiretsubject
chemistry.chemical_classificationmedicine.medical_specialtyHomocysteinebusiness.industryVascular diseaseGlutathione peroxidaseConfoundingmedicine.diseaseCoronary artery diseasechemistry.chemical_compoundEndocrinologychemistryInternal medicineCardiologyMedicineRisk factorCardiology and Cardiovascular MedicinebusinessRisk assessmentProspective cohort studydescription
Objectives This prospective study was designed to evaluate the effect of joint determination of two important contrary biomarkers—homocysteine and glutathione peroxidase (GPx)-1—on cardiovascular risk stratification. Background Homocysteine plasma levels have been associated with cardiovascular risk. Experimental data suggest that antioxidative GPx-1 activity modulates cardiovascular risk associated with homocysteine. Methods In 643 patients with coronary artery disease, we performed a prospective study to assess the risk of homocysteine plasma levels and GPx-1 activity on long-term cardiovascular risk with a median follow-up of 7.1 years. Results Both homocysteine and GPx-1 were among the strongest univariate predictors of future cardiovascular risk, even after adjustment for cardiovascular confounders. Homocysteine levels were significantly elevated in individuals with future cardiovascular events (15.4 vs. 13.4 μmol/l; p Conclusions Plasma homocysteine levels and GPx-1 activity are complementary in identifying individuals at high cardiovascular risk. Joint determination of both biomarkers provides substantial information on top of classic risk factors in cardiovascular risk assessment.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2005-05-01 | Journal of the American College of Cardiology |